Wells Fargo
RPTX

Wells Fargo’s Repare Therapeutics RPTX Stock Holding History

Wells Fargo’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,144
Closed -$3.94K – 7174
2024
Q3 		$3.94K Hold
1,144
– – ﹤0.01% 5960
2024
Q2 		$3.77K Sell
1,144
-4
-0.3% -$14 ﹤0.01% 5920
2024
Q1 		$5.41K Sell
1,148
-32
-3% -$205 ﹤0.01% 5877
2023
Q4 		$8.61K Sell
1,180
-12
-1% -$67 ﹤0.01% 5868
2023
Q3 		$14.4K Sell
1,192
-19
-2% -$196 ﹤0.01% 5709
2023
Q2 		$12.8K Sell
1,211
-35
-3% -$361 ﹤0.01% 5844
2023
Q1 		$12.3K Sell
1,246
-1,795
-59% -$20.6K ﹤0.01% 5793
2022
Q4 		$44.7K Buy
3,041
+1,977
+186% +$29.6K ﹤0.01% 4913
2022
Q3 		$13K Sell
1,064
-34,445
-97% -$443K ﹤0.01% 5588
2022
Q2 		$497K Buy
35,509
+35,215
+11,978% +$415K ﹤0.01% 3751
2022
Q1 		$4K Sell
294
-16
-5% -$237 ﹤0.01% 6539
2021
Q4 		$7K Sell
310
-310
-50% -$7.3K ﹤0.01% 6643
2021
Q3 		$16K Sell
620
-18
-3% -$581 ﹤0.01% 6050
2021
Q2 		$20K Sell
638
-880
-58% -$28.8K ﹤0.01% 5907
2021
Q1 		$47K Sell
1,518
-1,032
-40% -$35.1K ﹤0.01% 5839
2020
Q4 		$87K Buy
+2,550
New +$76.2K ﹤0.01% 5412

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo's RPTX Position: Q4 2024 in Review

Wells Fargo sold out of Repare Therapeutics (RPTX) in Q4 2024, closing a stake of 1,144 shares — an estimated $3.94K sold.

Wells Fargo first reported a position in RPTX in Q4 2020 and held it in 16 quarters. The position peaked at $497K in Q2 2022. 54 funds tracked by Wall St. Rank hold RPTX as of Q4 2024.

  • Wells Fargo reported no remaining Repare Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Wells Fargo sold 1,144 Repare Therapeutics shares in Q4 2024, an estimated $3.94K.
  • Wells Fargo first reported a position in Repare Therapeutics in Q4 2020 and held it in 16 quarters.
  • Wells Fargo's Repare Therapeutics position peaked at $497K in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2024.

Based on Wells Fargo's 13F filing for Q4 2024, filed 13 Feb 2025.